Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy.
Kuhlen M, Bleckmann K, Möricke A, Schrappe M, Vieth S, Escherich G, Bronsema A, Vonalt A, Queudeville M, Zwaan CM, Ebinger M, Debatin KM, Klingebiel T, Koscielniak E, Rossig C, Burkhardt B, Kolb R, Eckert C, Borkhardt A, von Stackelberg A, Chen-Santel C.
Kuhlen M, et al. Among authors: rossig c.
Br J Haematol. 2017 Oct;179(2):272-283. doi: 10.1111/bjh.14877. Epub 2017 Aug 2.
Br J Haematol. 2017.
PMID: 28771662
Free article.
Clinical Trial.